COVID-19 and Hyperimmune sera: A feasible plan B to fight against coronavirus
CBP da Costa, FJ Martins, LER da Cunha… - International …, 2021 - Elsevier
Since the very beginning of the COVID-19 pandemic, different treatment strategies have
been explored. These mainly involve the development of antimicrobial, antiviral, and/or anti …
been explored. These mainly involve the development of antimicrobial, antiviral, and/or anti …
Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases
T Tharmalingam, X Han, A Wozniak… - Human vaccines & …, 2022 - Taylor & Francis
Passive immunization with polyclonal hyper immunoglobulin (HIG) therapy represents a
proven strategy by transferring immunoglobulins to patients to confer immediate protection …
proven strategy by transferring immunoglobulins to patients to confer immediate protection …
[HTML][HTML] Immunoglobulin fragment F (ab') 2 against RBD potently neutralizes SARS-CoV-2 in vitro
X Pan, P Zhou, T Fan, Y Wu, J Zhang, X Shi, W Shang… - Antiviral research, 2020 - Elsevier
COVID-19, which is caused by the emerging human coronavirus SARS-CoV-2, has become
a global pandemic that poses a serious threat to human health. To date, no vaccines or …
a global pandemic that poses a serious threat to human health. To date, no vaccines or …
Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19
In the current global emergency due to SARS-CoV-2 outbreak, passive immunotherapy
emerges as a promising treatment for COVID-19. Among animal-derived products, equine …
emerges as a promising treatment for COVID-19. Among animal-derived products, equine …
Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with …
H Müller, SK Fehling, J Dorna, RA Urbanowicz… - npj Vaccines, 2020 - nature.com
Lassa mammarenavirus (LASV) is a rodent-borne arenavirus endemic to several West
African countries. It is the causative agent of human Lassa fever, an acute viral hemorrhagic …
African countries. It is the causative agent of human Lassa fever, an acute viral hemorrhagic …
Immunotherapeutics for ebola virus disease: hope on the horizon
KL O'Donnell, A Marzi - Biologics: Targets and Therapy, 2021 - Taylor & Francis
Ebola virus disease (EVD) remains among the biggest public health threats in Africa, even
though recently a vaccine was approved for human use. However, in outbreak situations …
though recently a vaccine was approved for human use. However, in outbreak situations …
Therapeutic strategies against Ebola virus infection
CH Liu, YT Hu, SH Wong, LT Lin - Viruses, 2022 - mdpi.com
Since the 2014–2016 epidemic, Ebola virus (EBOV) has spread to several countries and
has become a major threat to global health. EBOV is a risk group 4 pathogen, which …
has become a major threat to global health. EBOV is a risk group 4 pathogen, which …
[HTML][HTML] Development of horse neutralizing immunoglobulin and immunoglobulin fragments against Junín virus
X Pan, Y Wu, W Wang, L Zhang, G Xiao - Antiviral research, 2020 - Elsevier
Argentine haemorrhagic fever (AHF) is a rodent-borne disease with a lethality as high as~
30%, which is caused by the New World arenavirus, Junín virus (JUNV). It was once a major …
30%, which is caused by the New World arenavirus, Junín virus (JUNV). It was once a major …
Equine immunoglobulin fragment F (ab') 2 displays high neutralizing capability against multiple SARS-CoV-2 variants
Neutralizing antibody-based passive immunotherapy could be an important therapeutic
option against COVID-19. Herein, we demonstrate that equines hyper-immunized with …
option against COVID-19. Herein, we demonstrate that equines hyper-immunized with …
[HTML][HTML] Establishment and application of a surrogate model for human Ebola virus disease in BSL-2 laboratory
W Yang, W Li, W Zhou, S Wang, W Wang, Z Wang… - Virologica Sinica, 2024 - Elsevier
The Ebola virus (EBOV) is a member of the Orthoebolavirus genus, Filoviridae family, which
causes severe hemorrhagic diseases in humans and non-human primates (NHPs), with a …
causes severe hemorrhagic diseases in humans and non-human primates (NHPs), with a …